KRAS and familial pancreatic carcinoma: Morales et al. (2007) conducted a case-case study involving 121 pancreatic cancer patients and found that patients with K-ras-mutated tumors had a significantly lower intake of n-3 LC-PUFA compared to those with non-K-ras-mutated tumors [48].